View More View Less
  • 1 Freie Universität Berlin Institute of Pharmacy Königin-Luise-Str. 2+4 14195 Berlin Germany
  • | 2 Charité — University Medicine Berlin Institute of Microbiology and Hygiene Hindenburgdamm 27 12203 Berlin Germany
Open access

The resistance of commensal bacteria to first and second line antibiotics has reached an alarming level in many parts of the world and endangers the effective treatment of infectious diseases. In this study, the influence of the plant-derived natural saponins glycyrrhizic acid, β-aescin, α-hederin, hederacoside C, and primulic acid 1 on the susceptibility of vancomycin-resistant enterococci (VRE) against antibiotics of clinical relevance was investigated in 20 clinical isolates. Furthermore, the antibacterial properties of saponins under study against VRE were determined in vitro. Results reveal that the susceptibility of VRE against gentamicin, teicoplanin, and daptomycin was enhanced in the presence of the saponin glycyrrhizic acid. Most importantly, glycyrrhizic acid (1 mg/ml) diminished the minimal inhibitory concentration (MIC) of gentamicin in gentamicin low-level intrinsic resistant VRE from 2 − >8 mg/l to ≤ 0.125−1 mg/l. The adding of β-aescin, α-hederin, hederacoside C, and primulic acid 1 to the antibiotics under study showed, compared to glycyrrhizic acid, less influence on the antibiotic potency. Only glycyrrhizic acid (1 mg/ml) and α-hederin (0.2 mg/ml) showed weak antibacterial properties against the clinical isolates. Our study points towards a therapeutic potential of saponins in the coapplication with antibiotics for bacterial infections.

  • World Health Organization (2014): Antimicrobial Resistance Global Report on Surveillance. WHO Press, Geneva

    '', in Antimicrobial Resistance Global Report on Surveillance , (2014 ) -.

  • Bassetti M, Merelli M, Temperoni C, Astilean A: New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12, 22 (2013)

    Astilean A , 'New antibiotics for bad bugs: where are we ' (2013 ) 12 Ann Clin Microbiol Antimicrob : 22 -.

    • Search Google Scholar
  • Boucher HW, Talbot GH, Bradley JS, Edwards Jr JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48, 1–12 (2009)

    Bartlett J , 'Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America ' (2009 ) 48 Clin Infect Dis : 1 -12.

    • Search Google Scholar
  • Klare I, Witte W, Wendt C, Werner G: Vancomycin-resistente Enterokokken (VRE). Aktuelle Daten und Trends zur Resistenzentwicklung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55, 1387–1400 (2012)

    Werner G , 'Vancomycin-resistente Enterokokken (VRE) ' (2012 ) 55 Aktuelle Daten und Trends zur Resistenzentwicklung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz : 1387 -1400.

    • Search Google Scholar
  • Bonten MJ, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, Rice T, Weinstein RA: Epidemiology of colonisation of patients and environment with van-comycin-resistant enterococci. Lancet 348(9042), 1615–1619 (1996)

    Weinstein RA , 'Epidemiology of colonisation of patients and environment with van-comycin-resistant enterococci ' (1996 ) 348 Lancet : 1615 -1619.

    • Search Google Scholar
  • Uttley AH, Collins CH, Naidoo J, George RC: Vancomycin-resistant enterococci. Lancet 1(8575–8576), 57–58 (1988)

    George RC , 'Vancomycin-resistant enterococci ' (1988 ) 1 Lancet : 57 -58.

  • European Centre for Disease Prevention and Control (2013): Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Control, Stockholm

    '', in Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) , (2013 ) -.

  • Robert Koch-Institut (2013): Epidemiologisches Bulletin Nr. 33. Robert Koch-Institut, Berlin

    '', in Epidemiologisches Bulletin Nr. 33. Robert Koch-Institut, Berlin , (2013 ) -.

  • Kelesidis T, Humphries R, Uslan DZ, Pegues D: De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis 18(4), 674–676 (2012)

    Pegues D , 'De novo daptomycin-nonsusceptible enterococcal infections ' (2012 ) 18 Emerg Infect Dis : 674 -676.

    • Search Google Scholar
  • Fraher MH, Corcoran GD, Creagh S, Feeney E.: Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect 65(4), 376–378 (2007)

    Feeney E , 'Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin ' (2007 ) 65 J Hosp Infect : 376 -378.

    • Search Google Scholar
  • Raad II, Hanna HA, Hachem RY, Dvorak T, Arbuckle RB, Chaiban G, Rice LB: Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother 48(9), 3583–3585 (2004)

    Rice LB , 'Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin ' (2004 ) 48 Antimicrob Agents Chemother : 3583 -3585.

    • Search Google Scholar
  • Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA: Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 36(11), e146–e148 (2003)

    Press RA , 'Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid ' (2003 ) 36 Clin Infect Dis : e146 -e148.

    • Search Google Scholar
  • Tsai HY, Liao CH, Chen YH, Lu PL, Huang CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Liu JW, Sun W, Wang LS, Ko WC, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR: Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother 56(6), 3402–3405 (2012)

    Hsueh PR , 'Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010 ' (2012 ) 56 Antimicrob Agents Chemother : 3402 -3405.

    • Search Google Scholar
  • Hänsel R, Sticher O (2007): Pharmakognosie — Phyto pharmazie. Springer Medizin Verlag, Heidelberg

    Sticher O , '', in Pharmakognosie — Phyto pharmazie , (2007 ) -.

  • Wolters B: Saponine als pflanzliche Pilzabwehrstoffe. Planta 79(1), 77–83 (1968)

    Wolters B , 'Saponine als pflanzliche Pilzabwehrstoffe ' (1968 ) 79 Planta : 77 -83.

  • Favel A, Steinmetz M D, Regli P, Vidal-Ollivier E, Elias R, Balansard G: In vitro antifungal activity of triterpenoid saponins. Planta Med 60(1), 50–53 (1994)

    Balansard G , 'In vitro antifungal activity of triterpenoid saponins ' (1994 ) 60 Planta Med : 50 -53.

    • Search Google Scholar
  • Sung WS, Lee DG: The combination effect of Korean red ginseng saponins with kanamycin and cefotaxime against methicillin-resistant Staphylococcus aureus. Biol Pharm Bull 31(8), 1614–1617 (2008)

    Lee DG , 'The combination effect of Korean red ginseng saponins with kanamycin and cefotaxime against methicillin-resistant Staphylococcus aureus ' (2008 ) 31 Biol Pharm Bull : 1614 -1617.

    • Search Google Scholar
  • Kim HS, Han SS, Oh KW, Jeong TS, Nam KY: Effect of ginseng saponin on the antimicrobial activities of some antibiotics. Korean J Mycol 15(2), 87–91 (1987)

    Nam KY , 'Effect of ginseng saponin on the antimicrobial activities of some antibiotics ' (1987 ) 15 Korean J Mycol : 87 -91.

    • Search Google Scholar
  • Arabski M, Wasik S, Dworecki K, Kaca W: Laser interferometric and cultivation methods for measurement of colistin/ampicilin and saponin interactions with smooth and rough of Proteus mirabilis lipopolysaccharides and cells. J Microbiol Methods 77(2), 178–183 (2009)

    Kaca W , 'Laser interferometric and cultivation methods for measurement of colistin/ampicilin and saponin interactions with smooth and rough of Proteus mirabilis lipopolysaccharides and cells ' (2009 ) 77 J Microbiol Methods : 178 -183.

    • Search Google Scholar
  • Cirioni O, Myszka H, Dawgul M, Ghiselli R, Orlando F, Silvestri C, Brescini L, Kamysz W, Guerrieri M, Giacometti A: In vitro activity and in vivo efficacy of the saponin diosgenyl 2-amino-2-deoxy-β-d-glucopyranoside hydrochloride (HSM1) alone and in combination with daptomycin and vancomycin against Gram-positive cocci. J Med Microbiol 60, 1337–1343 (2011)

    Giacometti A , 'In vitro activity and in vivo efficacy of the saponin diosgenyl 2-amino-2-deoxy-β-d-glucopyranoside hydrochloride (HSM1) alone and in combination with daptomycin and vancomycin against Gram-positive cocci ' (2011 ) 60 J Med Microbiol : 1337 -1343.

    • Search Google Scholar
  • Kirchner N, Bauer JS, Miess H, Grob H: Mangelware Antibiotika: wie es zu der Entwicklungslücke kommen konnte. Dtsch Apoth Ztg 5, 48–53 (2014)

    Grob H , 'Mangelware Antibiotika: wie es zu der Entwicklungslücke kommen konnte ' (2014 ) 5 Dtsch Apoth Ztg : 48 -53.

    • Search Google Scholar
  • European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org

  • Sasakia K, Yonebayashia S, Yoshidaa M, Shimizua K, Aotsukaa T, Takayamab K: Improvement in the bioavailability of poorly absorbed glycyrrhizin via various nonvascular administration routes in rats. Int J Pharm 265(1–2), 95–102 (2003)

    Takayamab K , 'Improvement in the bioavailability of poorly absorbed glycyrrhizin via various nonvascular administration routes in rats ' (2003 ) 265 Int J Pharm : 95 -102.

    • Search Google Scholar
  • Takeda S, Ishthara K, Wakui Y, Amagaya S, Maruno M, Akao T, Kobashi K: Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 48(9), 902–905 (1996)

    Kobashi K , 'Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis ' (1996 ) 48 J Pharm Pharmacol : 902 -905.

    • Search Google Scholar
  • van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 14(11), 1093–1099 (1999)

    Schalm SW , 'Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial ' (1999 ) 14 J Gastroenterol Hepatol : 1093 -1099.

    • Search Google Scholar
  • Akasaka Y, Hatta A, Sato T, Leuschner J, Sasagawa C, Inoue H: Acute toxicity study of monoammonium glycyrrhizinate by single intravenous administration to CD-1 mice and CD rats. Jpn Pharmacol Ther 36(11), 1017–1023 (2008)

    Inoue H , 'Acute toxicity study of monoammonium glycyrrhizinate by single intravenous administration to CD-1 mice and CD rats ' (2008 ) 36 Jpn Pharmacol Ther : 1017 -1023.

    • Search Google Scholar
  • Cosmetic Ingredient Review Expert Panel: Final report on the safety assessment of glycyrrhetinic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate. Int J Toxicol 26(Suppl 2), 79–112 (2007)

    'Final report on the safety assessment of glycyrrhetinic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate ' (2007 ) 26 Int J Toxicol : 79 -112.

    • Search Google Scholar
The author instruction is available in PDF.
Please, download the file from HERE.
 

Senior editors

Editor(s)-in-Chief: Dunay, Ildiko Rita

Editor(s)-in-Chief: Heimesaat, Markus M.

Vice Editor(s)-in-Chief: Fuchs, Anja

Editorial Board

Chair of the Editorial Board:
Jeffrey S. Buguliskis (Thomas Jefferson University, USA)

  • Jörn Albring (University of Münster, Germany)
  • Stefan Bereswill (Charité - University Medicine Berlin, Germany)
  • Dunja Bruder (University of Megdeburg, Germany)
  • Jan Buer (University of Duisburg, Germany)
  • Jeff Buguliskis (Thomas Jefferson University, USA)
  • Edit Buzas (Semmelweis University, Hungary)
  • Charles Collyer (University of Sydney, Australia)
  • Renato Damatta (UENF, Brazil)
  • Ivelina Damjanova (Semmelweis University, Hungary)
  • Maria Deli (Biological Research Center, HAS, Hungary)
  • Olgica Djurković-Djaković (University of Belgrade, Serbia)
  • Jean-Dennis Docquier (University of Siena, Italy)
  • Anna Erdei (Eötvös Loránd University, Hungary)
  • Zsuzsanna Fabry (University of Washington, USA)
  • Beniam Ghebremedhin (Witten/Herdecke University, Germany)
  • Nancy Guillen (Institute Pasteur, France)
  • Georgina L. Hold (University of Aberdeen, United Kingdom)
  • Ralf Ignatius (Charité - University Medicine Berlin, Germany)
  • Zsuzsanna Izsvak (MDC-Berlin, Germany)
  • Achim Kaasch (University of Cologne, Germany)
  • Tamás Laskay (University of Lübeck, Germany)
  • Oliver Liesenfeld (Roche, USA)
  • Shreemanta Parida (Vaccine Grand Challenge Program, India)
  • Matyas Sandor (University of Wisconsin, USA)
  • Ulrich Steinhoff (University of Marburg, Germany)
  • Michal Toborek (University of Miami, USA)
  • Mary Jo Wick (University of Gothenburg, Sweden)
  • Susanne A. Wolf (MDC-Berlin, Germany)

 

Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildikodunay@gmail.com

Indexing and Abstracting Services:

  • PubMed Central
  • Scopus
  • ESCI
  • CABI

 

2020  
CrossRef Documents 23
WoS Cites 708
Wos H-index 27
Days from submission to acceptance 219
Days from acceptance to publication 176
Acceptance Rate 70%

2019  
WoS
Cites
558
CrossRef
Documents
24
Acceptance
Rate
92%

 

European Journal of Microbiology and Immunology
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge 928 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Gold Open Access
Purchase per Title  

European Journal of Microbiology and Immunology
Language English
Size A4
Year of
Foundation
2011
Publication
Programme
2021 Volume 11
Volumes
per Year
1
Issues
per Year
4
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2062-509X (Print)
ISSN 2062-8633 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 0 10 5
Jul 2021 0 3 1
Aug 2021 0 2 0
Sep 2021 0 8 3
Oct 2021 0 8 5
Nov 2021 0 6 5
Dec 2021 0 0 0